London, 16 August 2023: Today we’re delighted to announce that we have completed an $18m Series A round to scale up and continue our mission of running innovative and radically faster end-to-end clinical trials.
We use our technology platform to execute clinical trials from start to finish, helping treatments to reach patients more quickly to improve and extend the lives of those living with chronic illnesses.
The funding comes from Spotify-backer Creandum, with participation from PayPal co-founder Peter Thiel and returning investors firstminute, Seedcamp, Hambro Perks, Amino Collective, Page One Ventures and Calm/Storm. Additional investment has been provided by angel investors including Nadav Rosenberg, Kaysan Nikkhah, Trevor Martin, Soraya Darabi, Andrej Steinberg, Tom Krüger and Mithi Thaya.
Lead investor Creandum boasts an impressive portfolio of well-known companies, including Bolt, Klarna, Spotify, Depop, Tide, Trade Republic and Pleo. Creandum General Partner Fredrik Cassel, previously on the board at Spotify, will join the Lindus Health board. Meanwhile Peter Thiel was a co-founder of Paypal, Palantir and the first outside investor in Facebook.
Having already delivered more than 80 clinical trials across the US, UK and Europe, we are next launching trials for treatments for menopause, tinnitus, insomnia and childhood myopia. With this latest funding round, we will be expanding our technology platform to deliver more end-to-end clinical trials and higher quality data to research sponsors.
Launched in 2021 by Michael Young and Meri Beckwith, we’ve already worked with 20,000 patients to find new treatments for chronic conditions and improve lives. We now have a team of 40 from companies including Meta, Google, Oxford University and Optum Health, working across the US, UK and EU.
We’re currently hiring for a broad range of business development, clinical operations and operational roles - apply here.
Commenting on the raise, Michael Young, Co-Founder of Lindus Health, said: “Clinical trials are the biggest bottleneck to improving human health. We deliver clinical trials three times faster than the industry standard, working with biotech pioneers to get new treatments to patients more quickly.
Through this latest raise, we will be further investing in our technology platform so that we can deliver clinical trials in completely new ways.”
Meri Beckwith, Co-Founder of Lindus Health, said:
“The antiquated clinical trials industry is holding back healthcare. Everyone suffers from the status quo, especially patients, who must wait decades and pay higher prices for new treatments.
We’re excited to accelerate the pace and scale of our work with high-growth companies who will be responsible for the next wave of breakthrough treatments.This investment will help us achieve our vision of creating a much more agile and productive life sciences industry, for the benefit of all.”
Fredrik Cassel, General Partner at Creandum said:
“When we first met Michael, Meri and the rest of the Lindus Health team, we knew their approach to disrupting the clinical trials industry would be the right one. With a tech-first, AI-powered, end-to-end offering, Lindus Health is building unparalleled efficiency and quality into what has always been a manual process. We were blown away by the work Lindus is already doing across the US, UK and Europe with stellar customer feedback and references. The potential Lindus has on improving the world’s health is vast and we are excited to join them on this journey.”
About Lindus Health
Lindus Health is a London-based start-up with teams in the UK, US and Germany that runs clinical trials three times faster than the old-fashioned industry-standard – bringing ground-breaking treatments to patients more quickly. Clinical trials are the biggest bottleneck to advances in healthcare and by removing this constraint Lindus Health aim’s to improve health for everyone. Lindus does this by marring a world-class clinical operations team with its pioneering software platform that can manage a trial from start to finish.
From monitoring trial data in real-time to using machine learning to predict trial outcomes and make improvements to trial designs in advance, Lindus is simplifying and accelerating the trial process and putting patients first.
Lindus Health has to date delivered more than 80 trials across the UK, US and Europe to tackle a range of conditions including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia.
The company was named for James Lind, who pioneered the first clinical trial and treatment for scurvy, and was co-founded by Michael Young, a former No 10 Special Adviser on Life Sciences, and Meri Beckwith, a former Venture Capitalist focused on Life Sciences.
Lindus Health and Oto launch remote trial to combat tinnitus
We're excited to announce that we've launched a fully remote clinical study with Oto, a UK-based digital health startup, to combat tinnitus.
Why I joined Lindus Health - Anthony Brogno, Director of Clinical Operations
To break the mold of the CRO status quo. To leverage social medial and technology to support research operations. The Lindus Health culture. Hear more from Anthony Brogno, Director of Clinical Operations, on why he joined Lindus Health.
The FDA's DCT Draft Guidance: What's Missing?
The FDA recently released draft guidance on DCTs. Whilst this is a significant step towards providing a clear framework for implementing DCTs, some parts could be expanded on for the industry to take full advantage of their potential. We reflected on our learnings from delivering DCTs to highlight three key areas we think can benefit from additional detail: participant engagement, recruitment and retention, and the handling of investigational products.